Salivary immunoglobulin E levels in patients treated with Omalizumab

D. Hristova (Sofia, Bulgaria), R. Emilova (Sofia, Bulgaria), Y. Todorova (Sofia, Bulgaria), M. Aleksova (Sofia, Bulgaria), M. Nikolova (Sofia, Bulgaria)

Source: International Congress 2022 – Update on clinical trials in allergy, asthma and COPD

Session: Update on clinical trials in allergy, asthma and COPD
Session type: Thematic Poster
Number: 3200

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Hristova (Sofia, Bulgaria), R. Emilova (Sofia, Bulgaria), Y. Todorova (Sofia, Bulgaria), M. Aleksova (Sofia, Bulgaria), M. Nikolova (Sofia, Bulgaria). Salivary immunoglobulin E levels in patients treated with Omalizumab. 3200

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.